Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy

Mostrar otras versiones (1)

BACKGROUND: Sphingosine-1-phosphate receptor (S1P) modulators and anti-CD20 therapies impair humoral responses to SARS-CoV-2 mRNA vaccines. Relatively few studies have assessed the impact of an array of disease modifying therapies (DMTs) for multiple sclerosis (MS) on T cell immune responses to SARS...

Descripción completa

Detalles Bibliográficos
Autores principales: Gadani, Sachin P., Reyes-Mantilla, Maria, Jank, Larissa, Harris, Samantha, Douglas, Morgan, Smith, Matthew D., Calabresi, Peter A., Mowry, Ellen M., Fitzgerald, Kathryn C., Bhargava, Pavan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520057/
https://www.ncbi.nlm.nih.gov/pubmed/34666226
http://dx.doi.org/10.1016/j.ebiom.2021.103636

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520057/
https://www.ncbi.nlm.nih.gov/pubmed/34666226
http://dx.doi.org/10.1016/j.ebiom.2021.103636

Ejemplares similares